Ş. B. KARACA Et Al. , "Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy," ESMO Congress 2014 , vol.25, Madrid, Spain, pp.554, 2014
KARACA, Ş. B. Et Al. 2014. Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy. ESMO Congress 2014 , (Madrid, Spain), 554.
KARACA, Ş. B., SÜRMELİ, Z. G., GÜRSOY, P., ERDOĞAN, A. P., ŞANLI, U. A., & USLU, R., (2014). Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy . ESMO Congress 2014 (pp.554). Madrid, Spain
KARACA, ŞAZİYE Et Al. "Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy," ESMO Congress 2014, Madrid, Spain, 2014
KARACA, ŞAZİYE B. Et Al. "Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy." ESMO Congress 2014 , Madrid, Spain, pp.554, 2014
KARACA, Ş. B. Et Al. (2014) . "Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy." ESMO Congress 2014 , Madrid, Spain, p.554.
@conferencepaper{conferencepaper, author={ŞAZİYE BURÇAK KARACA Et Al. }, title={Trastuzumab/AT-101 combination induces apoptosis and shows synergistic cytotoxicity in HER-2 positive breast cancer cells by inhibition of PI3K signaling: A novel combination to overcome resistance to anti-HER2 therapy}, congress name={ESMO Congress 2014}, city={Madrid}, country={Spain}, year={2014}, pages={554} }